One Down, But More Remain: PDL Settles Patent Scrap With Alexion Over Soliris
This article was originally published in The Pink Sheet Daily
One-time $25M payout for license ends dispute over royalties for hemoglobinuria therapy.
You may also be interested in...
Troubled biotech spins off R&D, leaves shell to manage royalty income.
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.
Soliris is slated to launch within two weeks from its March 16 approval.